Elamipretide
Also called SS-31, MTP-131, Forzinity.
Elamipretide has FDA-approved products for specific uses. This page cites 2 sources, and the strongest evidence comes from human trials.
- Status
- FDA-approved product exists
- Form
- Injection
- Half-life
- Not modeled
- Strongest evidence
- Human trials
- Cited claims
- 1
- Last updated
- November 6, 2026
What the evidence says
Each claim names the kind of study behind it, what it can't tell you, and where it comes from.
Human trials
In the 12-person TAZPOWER crossover trial, elamipretide did not outperform placebo on six-minute walk distance or Barth syndrome fatigue scores during 12-week treatment periods.
Limits: Later knee-extensor-strength improvements occurred during the uncontrolled extension. These findings in the same small group cannot establish causality or prove benefit in healthy people. FDA granted accelerated approval while requiring confirmation of clinical benefit.
Regulatory status
United States
Forzinity received FDA accelerated approval on September 19, 2025, to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg. It is a subcutaneous injection. Approval relies on knee-extensor strength as an intermediate clinical endpoint; confirmatory clinical benefit remains required.